S01E34 | CORAL Trial: Nalbuphine for IPF Cough — A Real Signal?

In this episode of PRISM Rounds, we break down the CORAL randomized clinical trial published in JAMA evaluating nalbuphine extended-release for chronic cough in idiopathic pulmonary fibrosis (IPF).In this episode, we discuss:The magnitude of cough reduction (~50–60% vs ~17% placebo)Why objective cough monitoring changes trial designDose-response and patient-reported outcomesSafety of a κ-opioid agonist / μ-antagonist strategyWhat this means for pulmonary and critical care practiceThis is one of the first trials to show a strong, clinically meaningful signal for treating IPF-associated cough—an area of major unmet need.📄 PubMed (CORAL Trial):https://pubmed.ncbi.nlm.nih.gov/38265368/📄 JAMA Article:https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.26179PRISM Rounds is an audio journal club designed for clinicians who want high-yield, bedside-relevant discussions of new evidence.Tags#FOAMed #CriticalCare #Pulmonary #IPF #InterstitialLungDisease #ILD #ChronicCough #JAMA #RCT #EvidenceBasedMedicine #MedEd #MedicalPodcast #ICU #Respiratory #PulmCrit #JournalClub #Pharmacology #Opioid #Nalbuphine #ClinicalTrials #Healthcare #Medicine #Physicians #MedTwitter #PodcastMedicine #ATS #ERS